Lacosamide Milpharm

Lacosamide, the active ingredient in Lacosamide Milpharm, is a sodium channel modifier presented as an oral formulation for oral use. It is used as adjunctive therapy for partial‑onset seizures in patients who require additional seizure control.

GNH USA supplies Lacosamide Milpharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an antiepileptic drug that targets neuronal hyperexcitability in focal seizure disorders. - Partial‑onset seizures: provides adjunctive seizure reduction when added to existing antiepileptic regimens. - Focal seizures with secondary generalization: helps control seizure spread and frequency. - Refractory focal epilepsy: offers an additional therapeutic option for patients not adequately controlled by other agents.

Lacosamide may cause a range of adverse reactions, from mild to serious. Monitoring and reporting of side effects are essential for patient safety.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Nausea: mild to moderate gastrointestinal upset. - Fatigue: generalized tiredness or lack of energy. - Headache: mild to moderate cranial discomfort. - Blurred vision: temporary visual disturbances. - Diplopia: double vision, especially at higher doses.

Serious or Rare Side Effects: - Cardiac arrhythmia: alterations in heart rhythm, including PR‑interval prolongation. - Suicidal ideation: emergence of thoughts of self‑harm. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hypersensitivity: rash, angioedema, or anaphylaxis. - Liver enzyme elevation: abnormal hepatic function tests. - Blood dyscrasias: leukopenia or thrombocytopenia.

Patients should be evaluated for specific risk factors before initiating lacosamide therapy. - Renal impairment: assess kidney function and adjust monitoring as needed. - Hepatic impairment: evaluate liver status and consider dose adjustments. - Concomitant CNS depressants: monitor for additive sedation or respiratory depression. - Pregnancy: risk category unknown; discuss potential benefits and risks with a healthcare professional. - Discontinuation: avoid abrupt cessation; taper under medical supervision to reduce seizure recurrence. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Lacosamide can interact with several drug classes, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase lacosamide plasma concentrations. - Carbamazepine: may reduce lacosamide levels, diminishing therapeutic effect.

Moderate Interactions (Monitor Closely): - Other antiepileptic drugs: monitor overall seizure control and side‑effect burden. - Alcohol: can enhance central nervous system depression. - Cardiac drugs affecting PR interval (e.g., beta‑blockers): monitor ECG for conduction changes.